UPDATE: Chardan Capital Markets Starts Senti Biosciences, Inc. (SNTI) at Buy, PT $12
- Wall St posts third straight quarterly loss as inflation weighs, recession looms
- Intel's Autonomous Unit Mobileye Files U.S. IPO, Defying Weak Market Conditions
- Nike (NKE) Drops 9% as Inventory Surges 44%, Analysts See Attractive Valuation
- Hollywood Super Agent Attempts to Open Door for Twitter-Musk Settlement - Bloomberg
- Dollar up on euro as quarter ends, commodity led currencies sink
Chardan Capital Markets analyst Geulah Livshits initiates coverage on Senti Biosciences, Inc. (NASDAQ: SNTI) with a Buy rating and a price target of $12.00.
The analyst comments "We initiate coverage of Senti Biosciences with a Buy rating (PT$12) on the potential of its gene circuit synthetic biology platform and engineered cell therapy pipeline to address several limitations of current cell and gene therapy modalities. Using its design-build-test-learn paradigm, Senti has developed a suite of technologies including logic-gates, calibrated-release cytokines, small-molecule regulated promoters, and promoters responsive to cell state. These modules can be used independently or in concert to achieve an optimized therapeutic profile across multiple modalities including various engineered cell therapy types as well as viral vectors. Senti's internal pipeline centers on donor-derived CAR NK cells going after validated targets for oncology, with 2 programs expected to enter the clinic in 2023. SENTI-202 targets CD33 and FLT3 for acute myeloid leukemia (AML), but includes a NOT logic gate to spare healthy hematopoietic stem cells (HSC) that also express these targets. SENTI-301 targets GPC3 for hepatocellular carcinoma (HCC) but additionally encodes a small-molecule regulated IL-12 transgene, to enable remodeling of the HCC tumor microenvironment (TME) while mitigating toxicity issues associated with high levels of systemic IL-12 exposure. A 3rd CAR NK program for colorectal cancer (CRC) that is about 1 year behind also uses the NOT gate architecture in conjunction with a CEACAM5-targeted CAR construct to spare healthy epithelial cells expressing safety antigen VSIG2. Senti's CAR NKs are additionally armed with a calibrated release IL-15 to enhance NK cell persistence and cytotoxic activity. We believe these approaches offer solutions to limitations of current therapies, and proof of concept can lay foundations for future programs, particularly in solid tumors where a multi-pronged approach is often needed to address the TME. Beyond its internal pipeline, Senti has collaborations with unrated Roche/Spark on synthetic cell type-specific promoters for gene therapies and with unrated Bayer/BlueRock on synthetic promoters and small molecule regulation for iPS cell-derived regenerative medicines."
Shares of Senti Biosciences, Inc. closed at $1.52 yesterday.
You May Also Be Interested In
- UPDATE: Cowen Starts Generac Holdings (GNRC) at Outperform
- Beiersdorf AG (BEI:GR) (BDRFY) PT Raised to EUR120 at HSBC
- S4 Capital Plc. (SFOR:LN) PT Raised to GBP2.55 at HSBC
Create E-mail Alert Related CategoriesAnalyst Comments, Hot Comments, Hot New Coverage, New Coverage
Related EntitiesChardan Capital Markets
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!